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Abstract 
Background: BoNT-A is often used in the clinical treatment for movement disorders. In recent years, various clinical 
studies suggest that BoNT-A can effectively alleviate pain caused by trigeminal neuralgia (TN); however, its mecha-
nism remains unclear.
Methods: In this study, we used a lab rat model for TN produced by chronic constriction injury of the infraorbital 
nerve (ION-CCI). Restrained rats were injected subcutaneously with BoNT-A into the whisker pad tissue (ipsilaterally to 
the nerve injury) 14 days after the ION-CCI. Allodynia was tested by Von Frey filaments and TRPs and cSNAP-25 were 
tested by western blot.
Results: Peripheral application of BoNT-A (3, 10 U/kg) significantly increased the pain threshold of ION-CCI rats. 
Rota-rod test showed that BoNT-A administration at doses tested did not significantly affect rat motor coordination. 
By probing for a specific marker for BoNT-A, cleaved synaptosomal-associated protein 25 (cSNAP-25), we found that 
peripheral application of BoNT-A (10 U/kg) affected brainstem Vc, which could be blocked by the axonal transport 
blocker colchicine. In addition, western blot analysis showed that in the Vc region of ION-CCI rats, the expression lev-
els of TRPA1, TRPV1, TRPV2 and TRPM8 increased, whereas peripheral application of BoNT-A significantly lowered the 
high expression of TRPA1, TRPV1 and TRPV2, but not TRPM8 at 7 days after BoNT-A injection.
Conclusions: The finding of this study suggest that peripherally applied BoNT-A can produce antinociceptive effects 
in ION-CCI model. The underlying mechanisms may be BoNT-A acts on the Vc via axonal transport, inhibits the high 
expression of TRPA1, TRPV1 and TRPV2, and reduces central sensitization.
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Background
Trigeminal neuralgia (TN) is episodic facial pain that is 
usually described to feel like a unilateral electric shock. 
This neuropathic disorder has been shown to be pro-
foundly distressing and to negatively impact the patient’s 
well-being (Hall et  al. 2006). According to epidemio-
logical studies, approximately 4–28.9/100,000 persons 
worldwide experience TN (Hall et  al. 2006; Dieleman 
et  al. 2008; Katusic et  al. 1990). Patients with TN usu-
ally present a clinical treatment challenge. The antiepi-
leptic drugs are usually used first in an attempt to treat 
TN. However, treatment with antiepileptic drugs results 
in more adverse reactions, and requires daily adminis-
tration. In addition, long-term use can cause a gradual 
decline of drug efficacy (Taylor et al. 1981).
Botulinum toxin type A (BoNT-A) is one of the sero-
types (A, B, C1, C2, D, E, F and G) of botulinum neu-
rotoxins derived from Clostridium botulinum (Setler 
2002). Brin et  al. (1987) reported the use of BoNT-A 
for treatment of dystonia, which results in relief of dys-
tonia symptoms, as well as significant pain experience 
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improvement in 74  % of the patients. Subsequently, the 
antinociceptive effects of BoNT-A are gradually recog-
nized (Luvisetto et al. 2015). With in-depth understand-
ing, several clinical studies indicate that BoNT-A can 
effectively alleviate TN (Zuniga et  al. 2008; Ngeow and 
Nair 2010; Bohluli et al. 2011). In 2012, we first used the 
RCT experimental method to demonstrate that BoNT-A 
can effectively alleviate the pain caused by TN with mild 
adverse reactions (Wu et  al. 2012). Subsequent stud-
ies further confirm the effectiveness of BoNT-A for the 
treatment of TN (Zhang et  al. 2014; Xia et  al. 2016; Li 
et al. 2014). However, the mechanism of BoNT-A treat-
ment for TN remains unclear. Currently, most studies on 
the mechanism of the antinociceptive effects of botuli-
num toxin focus on the formalin-induced pain model, as 
well as pre-application of BoNT-A to explore its role in 
pain prevention (Cui et al. 2004).
As most case of TN are caused by sensory nerve root 
compression (Zakrzewska and Linskey 2014), Vos et  al. 
(1994) developed a lab rat model of TN produced by 
chronic constriction injury of the infraorbital nerve 
(ION-CCI), which is a branch of the trigeminal nerve. 
This model reproduces important aspects of TN, includ-
ing signs of abnormal spontaneous pain-related behavior 
and mechanical allodynia (Vos et al. 1994).
The aim of the present study is to investigate the antin-
ociceptive effects of BoNT-A in the rat ION-CCI model, 
and whether BoNT-A exerts antinociceptive function by 
acting on the central nervous system. In addition, we also 
examined the potential central antinociceptive mecha-
nisms of BoNT-A.
Methods
Animals and trigeminal neuralgia model
Adult male Sprague-Dawley rats (Experimental Animal 
Center of Zhengzhou University) weighing 220–300 
were used. All rats were housed in climate-controlled 
rooms on a 12/12 light/dark cycle with water and stand-
ardized rodent diet available ad  libitum. The experi-
mental procedures were approved by the Commission 
of Zhengzhou University for ethics of experiments on 
animals in accordance with international standards (No. 
YFY2015096).
The trigeminal neuralgia model was performed by the 
method as described previously (Imamura et  al. 1997). 
Animals were anesthetized by a single intraperitoneal 
injection of 10  % chloral hydrate (0.2  ml/kg). All inci-
sions were made intraorally, which allowed the hair on 
the snout and vibrissae to remain intact. An incision 
approximately 10  mm long was made along the gin-
givobuccal margin. The incision was placed proximal to 
the first molar. The infraorbital nerve was dissected and 
two chromic catgut ligatures (4-0) were placed around 
the nerve spaced 2 mm apart. The ligatures reduced the 
diameter of the nerve by just a noticeable amount and 
they did not interrupt the epineural circulation. The inci-
sion was sutured at three points using 4.0 silk. The sham 
operation was identical except that the ION was not 
ligated.
Drug administration
BoNT-A (Hengli, Lanzhou, China) was reconstituted in 
adequate volume of 0.9  % saline. Restrained rats were 
injected subcutaneously with BoNT-A (30  μl) into the 
whisker pad tissue (ipsilaterally to the nerve injury) 
14 days after the ION-CCI using a Hamilton syringe nee-
dle (Hamilton Microliter 801, Hamilton, Bonaduz, Swit-
zerland). The dosed used were 3, and 10 U/kg BoNT-A, 
respectively. For control rats, 30  μl normal saline was 
injected.
Colchicine (Saxama, Wuhan, China) was reconsti-
tuted in normal saline to obtain the 5 mM concentration. 
Colchicine or normal saline (2  μl) was injected into the 
trigeminal ganglion (ipsilaterally to the nerve injury) of 
anesthetized rat as described previously (Neubert et  al. 
2005). The Hamilton syringe needle (Hamilton Micro-
liter 801, Hamilton, Bonaduz, Switzerland) was briefly 
inserted medially (1–2  mm) to the palpated portion of 
the zygomatic process through the infraorbital foramen. 
The needle was positioned at a 10 degree angle relative 
to the midline of the head. The tip of the needle was 
advanced approximately 20  mm along the infraorbital 
canal and subsequently through the foramen rotundum 
then the colchicines or isometric normal saline was 
injected.
Mechanical allodynia testing
Von Frey hairs (North coast medical Inc, Morgan Hill, 
CA) were used for mechanical stimulation. The filaments 
produced a bending force of 0.008, 0.02, 0.04, 0.07, 0.16, 
0.4, 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 10.0, 15.0, 26.0, 60.0, 
100, 200 and 300 g. Testing was performed as previously 
described in detail by Vos et al. (1994). In brief, a single 
rat is placed in a small transparent plastic cage for 10 min 
to accommodate to the experimental environment until 
they assumed their normal sniffing/no locomotion posi-
tion. Testers were not informed as to which rats had CCI 
or sham surgery. After the acclimatization sessions the 
tester was able to apply the von Frey hair to the ipsilat-
eral territory of the injury ION (whisker pad), starting at 
0.008 g, until a defined behavioral response was elicited. 
When rats showed positive reactions, the intensity was 
recorded, which was the pain threshold. Positive reac-
tions included (1) withdrawal reaction with rapid head 
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withdraw; (2) escape or aggressive behavior, manifested 
as escape, curling up, hiding its head, or biting or grasp-
ing the stimulant; (3) asymmetric face grooming, rat dis-
plays an uninterrupted series of at least three face-wash 
strokes directed to the stimulated facial area. If rats did 
not show any of the aforementioned reactions at the 
stimulation intensity of 26 g, then the pain threshold was 
given 26 g. Measurements were performed three times in 
ten min intervals and the mean of the measurements is 
used.
Rota‑rod test
To investigate whether BoNT-A has a systemic effect, we 
tested the effect of BoNT-A (at dose of 3 and 10 U/kg) on 
rat’s performance on the Rota-rod test. For the Rota-rod 
experimental apparatus (Ugo Basile, Italy), the rod diam-
eter was 6 cm, and the rotating speed was set to gradually 
increase from 5 to 40 r/min in 5 min. The latency for the 
rat to fall from the rotating rod was recorded. Each rat 
was subjected to four consecutive tests and results were 
averaged.
Western blot
The caudal subnucleus of the spinal trigeminal nucleus 
(Vc) was collected from deeply anesthetized, rapidly 
decapitated rats at designated time, either proceeded 
immediately for biochemical studies or kept at −80  °C 
until use. Western blot was performed as described pre-
viously (Xie et  al. 2014). Briefly, 30  μg of protein was 
separate by SDS-polyacrylamide gel electrophoresis 
(PAGE) and then transferred to PVDF membranes. After 
blocking in 5 % fat-free milk in Tris-buffered saline con-
taining 0.1  % Tween, immunoblots were probed with 
antibodies to cleaved synaptosomal-associated protein 
25 (cSNAP-25) (1:2000; GeneTex, USA), transient recep-
tor potential ankyrin 1 (TRPA1) (1:3000; Abcame, UK), 
transient receptor potential vanilloid type 1 (TRPV1) 
(1:1000, Sigma, USA), transient receptor potential vanil-
loid type 2 (TRPV2) (1:1500; Sigma, USA) and tran-
sient receptor potential vanilloid melastatin 8 (TRPM8) 
(1:1000; Abcame, UK). The same blots were stripped 
and reprobed with antibodies to β-actin (1:5000; Santa 
Crus, USA). The blots were then incubated with horse-
radish peroxidase (HRP)-conjugated secondary antibody 
(1:10,000, Boster, Wuhan, China) for 1 h at 37 °C. Immu-
noreactivity was visualized by chemiluminescence and 
exposure to a film. Band intensities were quantified by 
densitometric analysis using a densitometer.
Statistical analysis
All data is expressed as mean ±  SD. The statistical sig-
nificance was assessed using One-way ANOVA and 
the New-man-Keuls test. All statistical analyses were 
performed using SPSS 18.0. P < 0.05 was considered sta-
tistically significant.
Results
Antinociceptive effects of peripherally applied BoNT‑A
Von Frey hairs were used to examine the antimocicep-
tive effects of BoNT-A. Our results showed that 14 days 
after ION-CCI, the ipsilateral pain threshold of the ION-
CCI group was significantly reduced compared to the 
sham-operated group (P  <  0.05). BoNT-A (3, 10  U/kg) 
as injected subcutaneously into the ipsilateral whisker 
pad tissue 14  days after the ION-CCI. Four days after 
the subcutaneous injection with BoNT-A, pain thresh-
olds of each BoNT-A dose group significantly increased 
compared to the control group (P < 0.05). This antimoci-
ceptive effects reached a maximum level at 8  days and 
remained significantly elevated until 20 days. The 10 U/
kg group had better antimociceptive effects than the 3 U/
kg group; however, the difference between them was not 
statistically significant (P > 0.05) (Fig. 1).
Effects of BoNT‑A on rat motor coordination ability
BoNT-A (3, 10  U/kg) injected subcutaneously into the 
ipsilateral whisker pad did not affect the motor coordi-
nation ability of rats. Rota-rod test is a commonly used 
method to reflect the motor coordination ability of rats. 
Results of the Rota-rod test showed that 7  days after 
injection, the averaged latencies of rats to fall from the 
rotating rod of the two dose groups were not statistically 
significantly different from those of the control group 
(Table 1).
SNAP‑25 cleavage in Vc and central antinociceptive effects 
after BoNT‑A peripheral application is axonal transport 
dependent
Among the other Botulinum toxins, BoNT-A cleaves spe-
cific sites of synaptosomal-associated protein 25 (SNAP-
25) to inhibit the exocytosis of neurotransmitters from 
the nerve terminals. So, the cSNAP-25 can be used as a 
reliable marker of the BoNT-A diffusion and local action. 
Fourteen days after ION-CCI operation, BoNT-A (10 U/
kg) injection was performed. Seven days after BoNT-A 
injection, the level of cSNAP-25 in the Vc in the BoNT-A 
treatment group significantly increased compared to con-
trol group (P < 0.05). When axonal transport blocker col-
chicine was injected ipsilateral to BoNT-A injection into 
the trigeminal ganglion 12  h before the BoNT-A treat-
ment, BoNT-A (10  U/kg) failed to increase the level of 
cSNAP-25 (P > 0.05) in the Vc (Fig. 2). Behavioral studies 
also indicated that compared to the control group, ipsi-
lateral colchicine injection into the trigeminal ganglion 
resulted in disappearance of the antinociceptive effects of 
BoNT-A (10 U/kg) (P > 0.05) (Fig. 3).
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Effect of BoNT‑A on TRPs expression in Vc tissues
To obtain insight into the mechanisms of antinocicep-
tive effects of BoNT-A, the protein expression of TRPA1, 
TRPV1, TRPV2 and TRPM8 was further examined 
in ION-CCI model of trigeminal neuralgia. Western 
blot demonstrated that TRPA1 and TRPV1 expression 
increased remarkable at 14  days (P  <  0.05) after ION-
CCI and increased until 28  days (P  <  0.05), TRPV2 
increased remarkable at 7 days (P < 0.05) after ION-CCI 
and increased until 28 days (P < 0.05), TRPM8 expression 
started to increase at 7  days (P  <  0.05) after ION-CCI, 
reached a maximum level at 14 and remained signifi-
cantly elevated until 28  days (P  <  0.05) (Fig.  4a). While 
subcutaneously administration of BoNT-A (3, 10  U/
kg) significantly decreased the expression of TRPA1 
and TRPV1 at 7 days after BoNT-A injection in a dose-
related manner (P < 0.05). BoNT-A (10 U/kg rather than 
3 U/kg) significantly decreased the expression of TRPV2 
Fig. 1 Effect of BoNT-A on mechanical hypersensitivity induced by ION-CCI. Rats underwent either ION-CCI or sham operation. Fourteen days after 
the operation, BoNT-A (3, 10 U/kg) or normal saline was injected into the whisker pad ipsilateral to the operation site. Measurement were performed 
on the ipsilateral to the nerve injury. *P < 0.05 versus control group and #P < 0.05 versus CCI group
Table 1 Effects of BoBT-A on rat motor coordination ability 
(accessed by Rota-rod test)
* P > 0.05 versus Before BoNT-A treatment
3 U (s) 10 U (s)
Before BoNT-A treatment 268.2 ± 13.8 271.8 ± 16.6
Seven days after BoNT-A treatment 255.7 ± 8.5* 278.6 ± 11.4*
Fig. 2 Western blot analysis and quantitative analysis of cSNAP-
25 in Vc 7 days after BoNT-A treatment. β-actin was used as 
an internal standard. Only the representative Western blots of 
them are illustrated in this figure. Data were mean ± SD. (n = 6/
group). TG indicates injection into the trigeminal ganglion; WP 
indicates injection into the facial whisker pad. *P < 0.05 ver-
sus CCI + saline(TG) + saline(WP) group and #P < 0.05 versus 
CCI + saline(TG) + BoNT-A(WP) group
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at 7 days after BoNT-A injection. TRPM8 expression was 
not change significantly after BoNT-A (3, 10 U/kg) treat-
ment compared with control group (P > 0.05) (Fig. 4b).
Discussion
The application of BoNT-A has been recently explored in 
a number of pain associated disorders, such as diabetic 
neuropathy, complex regional pain syndrome, trigeminal 
neuralgia, and occipital neuralgia (Oh and Chung 2015). 
In recent years, a number of clinical studies have shown 
that BoNT-A treatment for TN is safe and effective 
(Zuniga et al. 2008; Ngeow and Nair 2010; Wu et al. 2012; 
Zhang et al. 2014; Li et al. 2014). However, the intrinsic 
limitations of clinical studies hamper the in-depth analy-
sis on its mechanism. In recent years, researchers have 
explored the treatment and mechanism of BoNT-A for 
pain associated with trigeminal nerve region (Matak et al. 
2011; Kim et al. 2015). However, these studies essentially 
use the formalin-induced inflammatory pain model and 
BoNT-A pretreatment method to study the mechanism. 
The features of formalin-induced inflammatory pain 
model are inconsistent with those of TN. In addition, 
BoNT-A pretreatment method is not a good clinical 
simulation of BoNT-A treatment for TN. The ION-CCI 
model is widely accepted as an appropriate model of 
trigeminal neuralgia (Vos et  al. 1994). In this study, we 
used the ION-CCI model of TN and examined the antin-
ociceptive effects of BoNT-A in successfully generated 
model, which is a good animal model for studying the 
clinical BoNT-A treatment for TN.
In this study, we found that BoNT-A significantly 
increased the mechanical stimulation threshold in rat 
ION-CCI model of trigeminal neuralgia, which is simi-
lar to the results observed in a previous study (Filipovic 
et al. 2012). However, most previous studies on the ION-
CCI model of TN use BoNT-A doses based on the doses 
used in other pain models. In this study, we found that 
differences in antinociceptive effects between different 
doses of BoNT-A in ION-CCI model of TN were not 
statistically significant, which is similar to the results of 
our previous clinical studies that there is no statistically 
significant differences in clinical efficacy between low-
dose (25U) and high-dose (75U) of BoNT-A treatment in 
TN patients (Zhang et  al. 2014). This also suggests that 
Fig. 3 Axonal transport blocker colchicine blocked antinociceptive effects of BoNT-A (10 U/kg). Rats underwent either ION-CCI or sham operation. 
Injection of BoNT-A (3, 10 U/kg) or normal saline into the whisker pad ipsilateral to the operation site was performed 14 days after the operation. 
Colchicine or normal saline was injected into ipsilateral trigeminal ganglion 12 h before the application of BoNT-A. TG indicates injection into the 
trigeminal ganglion; WP indicates injection into the facial whisker pad. *P < 0.05 versus CCI + saline(TG) + BoNT-A(WP) group
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the animal model and experimental method used in this 
study are consistent with the features of clinical BoNT-A 
treatment for TN.
The treatment mechanism of BoNT-A for TN is cur-
rently unclear. Most previous studies suggest that 
BoNT-A acts locally or on the trigeminal ganglia (Cui 
et al. 2004; Xiao et al. 2013). Vc is the primary relay for 
orofacial pain and temperature sensations and the site for 
processing sensory information, and plays an important 
role in the mechanism of TN pathogenesis. In this study, 
Fig. 4 The protein levels of TRPs. a, c Western blots analysis and quantitative of TRPA1, TRPV1, TRPV2 and TRPM8 at various times after ION-CCI. b, d 
Western blots analysis and quantitative of TRPA1, TRPV1, TRPV2 and TRPM8 at 7 days after BoNT-A or normal saline injection (21 days after operation) 
in 4 treatment groups. β-actin was used as an internal standard. Only the representative Western blots of them are illustrated in this figure. Data 
were mean ± SD (n = 6/group). TG indicates injection into the trigeminal ganglion; WP indicates injection into the facial whisker pad. *P < 0.05 
versus control and #P < 0.05 versus CCI group
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we used a specific BoNT-A marker, cSNAP-25, to deter-
mine the possible sites of BoNT-A action in the ION-CCI 
model of TN. By combining colchicine injection to block 
axonal transport, we proved that BoNT-A exerts antino-
ciceptive effects in brainstem Vc via axonal transport in 
the ION-CCI model of TN. The results are similar to the 
BoNT-A study results in other models (Matak et al. 2011, 
2012). Matak et  al. inject BoNT-A locally in the sciatic 
nerve area and detect cSNAP-25 in the corresponding 
spinal cord sections.
Since BoNT-A acts on the central nervous system 
through axonal transport, we examined whether BoNT-
A affects the motor coordination ability in rats. To the 
best of our knowledge, this study first used Rota-rod test 
to demonstrate that BoNT-A injection into facial trigem-
inal nerve region did not cause systemic effects in rats 
even at high doses (10 U/kg). This suggests that BoNT-
A exerts specific antinociceptive function in the central 
nervous system without affecting its other functions.
In recent years, TRPs have been identified as nonse-
lective cation channel proteins localized in the plasma 
membrane and membranes of intracellular organelles. A 
significant difference between TRPs family proteins and 
other ion channel family proteins is that members of TRP 
family share low homology and can be activated or sensi-
tized by a variety of mediators and ligands. It is currently 
recognized that TRPA1, TRPV1, TRPV2 and TRPM8 
play an important role in the pathogenesis of pain sen-
sation production and hyperalgesia (Ferrandiz-Huertas 
et  al. 2014), and are involved in the perception of pain 
induced by chemical, temperature or mechanical stimuli 
(Mickle et al. 2015). Most previous studies on ION-CCI 
model of TN focus on pathological changes of trigemi-
nal ganglia. To the best of our knowledge, this study first 
demonstrated that TRPA1, TRPV1, TRPV2 and TRPM8 
expression elevated in the Vc in ION-CCI model of TN, 
and BoNT-A effectively inhibited the high expression of 
TRPA1, TRPV1 and TRPV2. This suggests that BoNT-A 
is able to reduce central sensitization and therefore exerts 
antinociceptive function by inhibiting the high expres-
sion of nociceptors, such as TRPA1, TRPV1 and TRPV2. 
In addition, we also found that BoNT-A had no effect on 
the increased expression of TRPM8, hence suggesting 
BoNT-A does not affect TRPM8 expression. However, 
the effects of BoNT-A on TRPM8 require further study 
to confirm.
Conclusions
In conclusion, our findings suggest that peripherally 
applied BoNT-A can produce antinociceptive effects 
in ION-CCI model. The underlying mechanisms may 
be BoNT-A directly acts on the Vc via axonal trans-
port, inhibits the high expression of TRPA1, TRPV1 and 
TRPV2, and reduces central sensitization. This study pro-
vides not only a theoretical basis for clinical application 
of BoNT-A for TN treatment and other pain associated 
disorders, but also a new direction for understanding the 
antinociceptive mechanism of BoNT-A.
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